Trial reportDigestive diseases and sciences2021
Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study.
Trial report in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation for viral diseases: A systematic review of clinical trials.PloS one · 2024Pooled it
- Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases.Chinese medical journal · 2022Pooled it
- Health Effects of Drinking Water Produced from Deep Sea Water: A Randomized Double-Blind Controlled Trial.Nutrients · 2022Trial
- Trial
- Decoding Microbiota-Immune Interplay in Viral Pathogenesis: Toward Next-Generation Antiviral Therapies.Probiotics and antimicrobial proteins · 2026Review
- Short-chain Fatty Acids and Bile Acids Signaling in Chronic Hepatitis B.Journal of clinical and translational hepatology · 2026Review
- HBV and the Microbiome-PubMed Database Literature Review.Infectious disease reports · 2026Review
- Fecal microbiota transplantation in chronic liver disease: Current and future state of the art.Hepatology communications · 2026Review
- Methodological insights into fecal microbiota transplantation: Dissecting key approaches for success.World journal of methodology · 2026Review
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- Expert Consensus on Clinical Applications of Fecal Microbiota Transplantation for Chronic Liver Disease (2025 edition).Journal of clinical and translational hepatology · 2025Article
- Hepatitis B Virus-Related Liver Disease and Gut Microbiota: An Updated Review.Microorganisms · 2025Review
- The Gut Microbiome in Enteric Viral Infections: Underlying Mechanisms and Therapeutic Approaches.Microorganisms · 2025Review
- Machine learning as an artificial intelligence application in management of chronic hepatitis B virus infection.World journal of gastroenterology · 2025Article
- Yi-Qi-Xuan-Fei Formula ameliorate chronic obstructive pulmonary disease by remodeling lung and intestinal florase in rat models.Journal of food and drug analysis · 2025Article
- [Expert consensus on the clinical application of gut microbiota transplant therapy in chronic liver disease (version 2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Microbiome-Immune Interaction and Harnessing for Next-Generation Vaccines Against Highly Pathogenic Avian Influenza in Poultry.Vaccines · 2025Review
- Fecal microbiota transplantation: A promising treatment strategy for chronic liver disease.World journal of gastroenterology · 2025Review
- Long-term safety of fecal microbiota transplantation in Chinese children from 2013 to 2023: a single-center retrospective study.BMC microbiology · 2025Article
- Gut‑liver axis in liver disease: From basic science to clinical treatment (Review).Molecular medicine reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntestinal flora plays a critical role in immunity against hepatitis B virus (HBV). Fecal Microbiota Transplantation (FMT) may be a potential immunomodulatory therapy in patients with chronic hepatitis B (CHB).
aimWe aimed to study role of FMT in hepatitis B e antigen (HBeAg)-positive CHB patients in terms of its effect on HBeAg, HBsAg, and HBV DNA.
methodsHBeAg-positive patients despite being on antiviral treatment for > 1 year were given six cycles of FMT via gastroscope (nasoduodenal route) at 4 weekly intervals along with antiviral therapy. Twelve out of 14 included patients in FMT arm completed six cycles. Another 15 HBeAg-positive patients who were on oral antivirals for > 1 year were taken as control-antiviral therapy (AVT) arm. Per-protocol analysis was done.
resultsThe median (interquartile range) age in the FMT and AVT arm were 29 (25-35) and 29(24-38), respectively (P = 0.794). The median (interquartile range) duration of AVT prior to inclusion in the study was 80 (52-104) and 76 (52-114) months in FMT and AVT arm, respectively (P = 0.884). In the FMT arm, 16.7% (2/12) patients had HBeAg clearance in comparison to none in the AVT arm (P = 0.188). None of the patients in either arm had HBsAg loss. The FMT was tolerated well, 42.8% (6/14) patients reported one or more minor adverse events.
conclusionsIn this non-randomized pilot study, FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in patients with HBeAg-positive CHB. Further randomized controlled trials are needed in order to obtain robust conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.